FDA
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Raised to $58 at H.C. Wainwright
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $51 at Piper Sandler
-
-
-
-
-
-
-
Jefferies Assumes Scholar Rock (SRRK) at Buy
-
-
-
-
-
-
-
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
-
-
-
-
-
-
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
-
-
-
-
-
-
-
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
-
-
-
-
-
-
-
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

